DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2016-06-14

Last Posted Date: 2018-12-31

Lead Sponsor: AbbVie

Target Recruit Count: 40

Registration Number: NCT02798315

Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting

Completed

Conditions: Hidradenitis Suppurativa

First Posted Date: 2016-06-01

Last Posted Date: 2020-01-09

Lead Sponsor: AbbVie

Target Recruit Count: 236

Registration Number: NCT02786576

Locations: 🇧🇪
Meuleman, Lede, BE /ID# 154238, Lede, Belgium
🇨🇿
Vojenska nemocnice /ID# 163592, Olomouc, Czechia
🇨🇿
Kozni sanatorium /ID# 163591, Praha, Czechia

and more 80 locations

Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate

Withdrawn

Conditions: Rheumatoid Arthritis (RA)

First Posted Date: 2016-06-01

Last Posted Date: 2018-11-26

Lead Sponsor: AbbVie

Registration Number: NCT02786563

Locations: 🇨🇳
Peking University Peoples Hospit /ID# 148961, Beijing, Beijing, China
🇨🇳
Xijing Hospital /ID# 148960, Xian, Shaanxi, China
🇨🇳
Renji Hosp, Shanghai Jiaotong /ID# 148959, Shanghai, China

and more 1 locations

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

Phase 2

Active, not recruiting

Conditions: Crohn's Disease (CD)

Interventions: Drug: ABT-494

First Posted Date: 2016-05-25

Last Posted Date: 2024-06-17

Lead Sponsor: AbbVie

Target Recruit Count: 107

Registration Number: NCT02782663

Locations: 🇺🇸
Virginia Mason Hospital & Medical Center /ID# 150042, Seattle, Washington, United States
🇺🇸
University of Washington /ID# 149988, Seattle, Washington, United States
🇺🇸
Duplicate_University of Florida - Archer /ID# 150033, Gainesville, Florida, United States

and more 58 locations

This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Caffeine
Drug: Warfarin
Drug: Omeprazole
Drug: Metoprolol
Drug: Midazolam
Drug: Risankizumab

First Posted Date: 2016-05-13

Last Posted Date: 2017-09-25

Lead Sponsor: AbbVie

Target Recruit Count: 21

Registration Number: NCT02772601

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Berlin, Germany

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Venetoclax

First Posted Date: 2016-04-29

Last Posted Date: 2023-04-10

Lead Sponsor: AbbVie

Target Recruit Count: 258

Registration Number: NCT02756611

Locations: 🇨🇦
Sunnybrook Health Sciences Ctr /ID# 147462, Toronto, Ontario, Canada
🇵🇹
IPO Porto FG, EPE /ID# 147389, Porto, Portugal
🇨🇭
Hopitaux Universitaires de Geneve /ID# 147930, Genève, Geneve, Switzerland

and more 64 locations

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Phase 3

Completed

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Venetoclax
Drug: Bortezomib
Drug: Placebo for venetoclax
Drug: Dexamethasone

First Posted Date: 2016-04-29

Last Posted Date: 2023-08-22

Lead Sponsor: AbbVie

Target Recruit Count: 291

Registration Number: NCT02755597

Locations: 🇫🇷
CHU Limoges - Dupuytren 1 /ID# 149292, Limoges CEDEX 1, Franche-Comte, France
🇮🇹
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 148942, Ancona, Italy
🇦🇺
Box Hill Hospital /ID# 149112, Box Hill, Victoria, Australia

and more 94 locations

Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)

Completed

Conditions: Psoriatic Arthritis
Crohn's Disease
Ankylosing Spondylitis
Ulcerative Colitis
Rheumatoid Arthritis
Psoriasis

Interventions: Biological: Adalimumab
Behavioral: AbbVie Care 2.0

First Posted Date: 2016-04-26

Last Posted Date: 2019-11-06

Lead Sponsor: AbbVie

Target Recruit Count: 427

Registration Number: NCT02750800

Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Biological: Adalimumab

First Posted Date: 2016-04-15

Last Posted Date: 2019-08-09

Lead Sponsor: AbbVie

Target Recruit Count: 24

Registration Number: NCT02739828

Locations: 🇸🇪
Sodersjukhuset, Stockholm, Sweden
🇸🇪
Blekinge Hospital, Karlskrona, Sweden
🇸🇪
Hallands Hospital Halmstad, Halmstad, Sweden

and more 8 locations

Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

Completed

Conditions: Ulcerative Colitis (UC)

First Posted Date: 2016-04-14

Last Posted Date: 2024-12-31

Lead Sponsor: AbbVie

Target Recruit Count: 265

Registration Number: NCT02738125

Locations: 🇫🇷
CHU La Réunion - site St Denis - Félix-Guyon /ID# 151556, Saint-Denis, France
🇫🇷
Cabinet Medical /ID# 155460, BAIE Mahault, Guadeloupe, France
🇫🇷
CHU Toulouse - Hopital Purpan /ID# 167179, TOULOUSE Cedex 9, Haute-Garonne, France

and more 77 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy